EUVIMEDEUVIMED entdecken
Crossref

Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT

Michelle L Schoettler iD, Robert Lisac iD, Joel Ofori, Erin Frost, Wayne Liang, Suhag Parikh, Shanmuganathan Chandrakasan, Taylor Fitch, Jeremy Obordo, Kathleen Spencer, Satheesh Chonat, Adrianna Westbrook und 1 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Michelle L Schoettler und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation, Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complement C5 inhibition can be used to treat hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA) but may impact infectious organism clearance, impeding opsonization and lysis. The infectious risks of eculizumab exposure after hematopoietic cell transplant (HCT) are unknown. In this single center, retrospective case–control study, we included allogeneic HCT recipients transplanted from January 2019 to January 2023. All patients with TA‐TMA treated with eculizumab from day 14–180 post HCT were identified as cases. Controls were matched using an exact matching procedure on maximum grade 3–4 acute GVHD and intensive care unit admission. Cases and controls were matched on index date (first day of eculizumab therapy), and infections from 1 year of index date were captured. Among 31 pairs (62 patients), the rate of bacteremia was 8.49 times higher (95% CI 4.4, 16.4), tissue specific bacterial infections 6.22 times higher (95% CI 2.28, 17.17), and viral infections 3.16 times higher (95% CI 1.90, 5.25) in eculizumab exposed children compared to matched controls. After adjusting for the number of immune suppressive medications, steroid days exposed, and steroid refractory GVHD, all infection rates remained significantly higher among eculizumab exposed patients. In sensitivity models excluding an outlier and altering the study follow up time to 3 and 6 months, rates of infections remained significantly higher in the eculizumab cohort. Infection related mortality was significantly higher in the eculizumab exposed patients than controls; 1‐yr mortality was 45% vs 19% respectively. This study suggests infectious complications are increased with eculizumab treatment in the HCT setting, though additional studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedThrombotic MicroangiopathiesHematopoietic Stem Cell TransplantationInfectionsComplement Inactivating AgentsHumansChildMaleFemaleChild, PreschoolRetrospective StudiesCase-Control StudiesAdolescentInfantBacteremiaVirus Diseases

Stichwörter der Autor:innen

complement inhibitionhematopoietic cell transplant associated thrombotic microangiopathyinfection related mortalityinfections in imunocompromised hostsmarrow/stem cell transplantation‐organ specific toxicity

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA.
  • Department of Pediatrics, Pediatric Biostatistics, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Michelle L Schoettler, Robert Lisac

Förderung

  • American Society of Hematology

Zitieren

APA

Schoettler, M. L., Lisac, R., Ofori, J., Frost, E., Liang, W., Parikh, S., Chandrakasan, S., Fitch, T., Obordo, J., Spencer, K., Chonat, S., Westbrook, A., & Williams, K. M. (2025). Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT. American Journal of Hematology. https://doi.org/10.1002/ajh.70022

Vancouver

Schoettler ML, Lisac R, Ofori J, Frost E, Liang W, Parikh S, et al. Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT. American Journal of Hematology. 2025. doi:10.1002/ajh.70022

BibTeX
@article{Schoettler2025,
  author = {Schoettler, Michelle L and Lisac, Robert and Ofori, Joel and Frost, Erin and Liang, Wayne and Parikh, Suhag and Chandrakasan, Shanmuganathan and Fitch, Taylor and Obordo, Jeremy and Spencer, Kathleen and Chonat, Satheesh and Westbrook, Adrianna and Williams, Kirsten M},
  title = {Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70022}
}
Kostenlos starten →